Exhaustion · people receiving dialysis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthenia · people receiving dialysis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · people receiving dialysis
1 finding from 1 review
Weakness · people receiving dialysis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Energy · people receiving dialysis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypoglycaemic episodes a) Non‐serious hypoglycaemia
It is very uncertain whether DPP‐4 inhibitors changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
Adverse events other than hypoglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment satisfaction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HbA1c (%)
1 finding from 1 review
Hypoglycaemic episodes a) Non‐serious hypoglycaemia
It is very uncertain whether SGLT‐2 inhibitors changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemia
It is very uncertain whether SGLT‐2 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment satisfaction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HbA1c (%)
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypoglycaemic episodes a) Non‐serious hypoglycaemia
It is very uncertain whether GLP‐1 analogues inhibitors changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than hypoglycaemia
It is very uncertain whether GLP‐1 analogues inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
1 finding from 1 review